Global IPO Calendar: US and Europe Listings — 2026-09-08
The US IPO pipeline heats up this week with Holtec Nuclear launching a massive $825 million Nasdaq offering and Oura Health filing its S-1 for a potential $16 billion listing. Meanwhile, European markets face a bifurcated landscape, with London’s outlook darkening as firms defer to 2027, while Frankfurt sees mixed performance amid geopolitical tensions.
Global IPO Calendar: US and Europe Listings — 2026-09-08
Top developments
Holtec Nuclear launches year’s largest pure-play nuclear IPO
Holtec Nuclear Corporation announced the launch of its initial public offering on September 8, 2026, targeting a raise of approximately $825 million. The company set its price range at $15.00 to $18.00 per share for 50 million Class A common shares, with an additional option for underwriters to purchase up to 7.5 million more shares. Led by J.P. Morgan and Goldman Sachs, this listing represents one of the most significant energy sector debuts of the year, capitalizing on renewed investor interest in nuclear infrastructure
Oura Health files for Nasdaq listing with $1.4B revenue
Smart ring maker Oura filed a public S-1 registration statement on September 3, 2026, revealing trailing twelve-month revenue of $1.4 billion and 5 million paid members. The filing positions the company for a potential valuation exceeding $16 billion upon its anticipated Nasdaq debut. This move signals strong institutional appetite for consumer health tech companies with proven revenue models, contrasting with earlier years’ losses-heavy listings
London IPO market outlook dims as firms eye 2027
Financial News reports that the London IPO market is facing its bleakest outlook in modern times, with companies increasingly postponing listings until the 2027 window. Fundraising in the first half of 2025 had already fallen to a three-decade low, and current geopolitical uncertainty continues to suppress new issues. This trend highlights a growing divergence between US and UK capital markets, with US exchanges absorbing demand that might have previously gone to London
Tech IPO market remains narrow despite mega-deal headlines
Markets Insider analysis suggests that 2026’s tech IPO market is "shaping up to be another dud" if two mega-IPOs are excluded from the data. While headline-grabbing listings dominate news cycles, the broader pipeline for mid-cap tech firms remains thin, reflecting cautious investor sentiment and high valuation hurdles. This concentration risk underscores the difficulty for smaller tech firms to find viable exit windows in the current economic climate
Local view
Germany (Frankfurt/SIX): German financial outlet finanzen.net highlights a "half-time balance" of 2026 IPOs, noting that a lesser-known secondary market stock has doubled in value, outperforming high-profile names like SpaceX in terms of percentage gain. The coverage emphasizes that while mega-IPOs capture attention, steady performers in the Nebenwerte (small/mid-cap) segment are delivering tangible returns to retail investors. Additionally, tagesschau.de notes the successful debut of Chinese robot maker Unitree, which saw its share price surge over 600% above its issue price, though it warns that its valuation far exceeds current business fundamentals
France (Euronext): FranceTransactions.com continues to track the post-listing performance of Pasqal, the French quantum computing firm that listed in late August. The outlet focuses on the company's Nasdaq ambitions and the potential for further capital raises, noting that the initial €170 million raise was just the first step in a larger strategy to compete with US quantum firms. Local analysts are watching closely to see if Pasqal can maintain momentum amidst broader European tech sector volatility
Context & numbers
US Market Volume & Performance: While specific weekly US pricing totals are limited in recent reports, the Renaissance Capital and IPOScoop calendars indicate a steady stream of filings, with Oura and Holtec representing the largest active deals this week. The US market continues to favor sectors with clear revenue paths, such as health tech and energy infrastructure
European Pipeline Constraints: PitchBook’s Q3 2026 report notes that Europe’s IPO window remains "wide" due to favorable macro conditions, but the backlog of high-quality candidates is narrowing. This scarcity of prime assets is forcing investors to look further afield or wait for the next cohort of mature startups to reach listing readiness
Global Sentiment: CNBC market updates for September 7 indicate that European stocks finished mixed, with investor attention divided between US-Iran geopolitical developments and inflation data. This macro uncertainty contributes to the hesitation among European issuers to price deals aggressively
On the radar
- Anthropic IPO Speculation: German trading blog kagels-trading.de reports rumors that AI giant Anthropic is planning an IPO for October 2026, with potential indirect exposure available via Alphabet and Amazon. No official filing has been made yet
- Holtec Pricing Finalization: Investors should watch for the final pricing announcement for Holtec Nuclear later this week, which will confirm whether the deal prices at the top of the $15-$18 range, signaling strong institutional demand for nuclear energy stocks
- European Healthtech Watch: Healthcare.digital has released a list of top 10 European healthtech and medtech IPO candidates for 2026-2028, flagging several German and French firms that may file confidentially in the coming months
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
